Systematic Review and Single-Arm Meta-Analysis of Bevacizumab Combined with Chemotherapy or Immunotherapy for Oncological Outcomes in Advanced/Recurrent Ovarian Clear Cell Carcinoma.
메타분석
2/5 보강
TL;DR
Evaluating the oncological outcomes related to bevacizumab-based combination therapy among patients with advanced or recurrent ovarian clear cell carcinoma showed that bevacizumab significantly improved overall survival and progression-free survival.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: advanced or recurrent ovarian clear cell carcinoma (OCCC)
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The overall objective response rate (ORR), complete response (CR), and partial response (PR) were 49% (95% CI: 39-60%), 17% (95% CI: 9-25%), and 31% (95% CI: 22-41%). Bevacizumab-based combination therapy may be a prospective strategy for advanced or recurrent OCCC.
OpenAlex 토픽 ·
Ovarian cancer diagnosis and treatment
PARP inhibition in cancer therapy
Angiogenesis and VEGF in Cancer
Evaluating the oncological outcomes related to bevacizumab-based combination therapy among patients with advanced or recurrent ovarian clear cell carcinoma showed that bevacizumab significantly improv
- 95% CI 0.40-0.66
- HR 0.51
APA
Yuling Gu, Yunxian Tang, et al. (2026). Systematic Review and Single-Arm Meta-Analysis of Bevacizumab Combined with Chemotherapy or Immunotherapy for Oncological Outcomes in Advanced/Recurrent Ovarian Clear Cell Carcinoma.. Cancer investigation, 44(5), 544-554. https://doi.org/10.1080/07357907.2026.2618578
MLA
Yuling Gu, et al.. "Systematic Review and Single-Arm Meta-Analysis of Bevacizumab Combined with Chemotherapy or Immunotherapy for Oncological Outcomes in Advanced/Recurrent Ovarian Clear Cell Carcinoma.." Cancer investigation, vol. 44, no. 5, 2026, pp. 544-554.
PMID
41728770 ↗
Abstract 한글 요약
The study aimed to evaluate the oncological outcomes related to bevacizumab-based combination therapy among patients with advanced or recurrent ovarian clear cell carcinoma (OCCC). PubMed, Web of Science, Cochrane Library and Embase were searched, and the Newcastle-Ottawa Scale (NOS) was utilized to assess the study quality. Results showed that bevacizumab significantly improved overall survival (OS) (HR = 0.51; 95% CI: 0.40-0.66) and progression-free survival (PFS) (HR = 0.42; 95% CI: 0.29-0.60). The overall objective response rate (ORR), complete response (CR), and partial response (PR) were 49% (95% CI: 39-60%), 17% (95% CI: 9-25%), and 31% (95% CI: 22-41%). Bevacizumab-based combination therapy may be a prospective strategy for advanced or recurrent OCCC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Sunitinib induces immunogenic cell death through eIF2α phosphorylation to potentiate immunotherapy in HCC.
- The gut-liver axis modulates intestinal immune homeostasis.
- Hexavalent chromium promotes malignant transformation via enhanced translation of SUV39H1.
- Response to Letter to the Editor Regarding "Efficacy of Chinese Medicine on Postoperative Rehabilitation of Non-Small Cell Lung Cancer (NSCLC), a Randomized Controlled Study" in Integrative Cancer Therapies.
- Mothers' experiences of having a daughter with breast cancer in Chinese families: A qualitative study.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.